Akebia Therapeutics, Inc.’s AKBA share price has dipped by 22.21%, which has investors questioning if this is right time to ...

Chronic Kidney Disease (CKD) is a widespread and frequently under recognised condition impacting millions around the globe. With an ageing population, the prevalence of CKD is projected to rise ...

Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Critical. The battle against CKD is deeply personal, affecting individuals and families in profound ways. By prioritisng kidney health, Uganda can save lives, reduce the financial burden on families ...

Discover scPharmaceuticals' Q4 2024 achievements, including FUROSCIX's CKD approval, Medicare redesign insights, and strategies for 2025 growth.

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 millionCash and cash ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Up to 30% of acute kidney injury (AKI) survivors requiring dialysis and personalized care after discharge from the hospital.

The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050.